Harrow has entered into an agreement to acquire the exclusive U.S. commercial rights to five FDA-approved ophthalmic products from Novartis, according to a press release.
The binding agreement grants Harrow the U.S. rights to Ilevro (nepafenac ophthalmic suspension) 0.3% and Nevanac (nepafenac ophthalmic suspension) 0.1% for cataract surgery-associated pain and inflammation, Vigamox (moxifloxacin hydrochloride ophthalmic solution) 0.5% for treatment of bacterial conjunctivitis, Maxidex (dexamethasone ophthalmic suspension) 0.1% for the treatment of steroid-responsive inflammatory conditions of